Topic Hub
14 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 14 of 14 clinical reviews.
Step-by-step caregiver guidance for administering Evenity (romosozumab) subcutaneous injections to adolescents aged 12 to 17, including dosing, injection technique, storage, missed-dose protocol, and safety monitoring.
Read clinical reviewA physician-reviewed guide to romosozumab's effects on bone development, growth plates, hormonal axes, and long-term skeletal health in adolescents aged 12 to 17.
Read clinical reviewA clinician-reviewed guide on how adolescents aged 12-17 receiving romosozumab (Evenity) can manage school attendance, physical activity, sports participation, and daily routines safely.
Read clinical reviewA clinical guide to romosozumab (Evenity) in patients aged 65 and older, covering transitional care planning, fracture risk assessment, cardiovascular screening, and sequencing with antiresorptive therapy after the 12-month course.
Read clinical reviewComplete caregiver guide to administering Evenity (romosozumab) subcutaneous injections in adults aged 65 and older, including site selection, storage, missed-dose protocols, and cardiovascular monitoring requirements.
Read clinical reviewA clinical deep-dive into how romosozumab affects bone biology, fracture outcomes, and safety in adults aged 65 and older, with evidence from ARCH, FRAME, and current endocrine guidelines.
Read clinical reviewA clinical guide to romosozumab use in adults 65 and older, covering physical activity safety, fall prevention, cardiovascular risk, and practical scheduling for the ARCH and FRAME trial populations.
Read clinical reviewA clinical deep-dive into off-label romosozumab use in adolescents ages 12-17, covering mechanism, evidence base, dosing considerations, safety signals, and when pediatric bone specialists consider it.
Read clinical reviewA clinical deep-dive into romosozumab (Evenity) use in patients 65 and older, covering on-label indications, off-label scenarios, cardiovascular safety, dosing, and evidence from ARCH and FRAME trials.
Read clinical reviewA clinical review of romosozumab (Evenity) off-label use in pediatric patients under age 12, covering mechanism, available trial data, dosing considerations, safety signals, and when prescribers might consider it.
Read clinical reviewRomosozumab (Evenity) is FDA-approved only for postmenopausal women, not children under 12. Learn what the science says about its developmental risks, bone biology effects, and why pediatric use remains experimental.
Read clinical reviewComplete caregiver guidance on Evenity (romosozumab) administration for children under 12, including injection technique, storage, dosing schedules, and safety monitoring.
Read clinical reviewA clinician-reviewed guide covering school accommodations, physical activity restrictions, injection scheduling, and safety monitoring for children under 12 receiving romosozumab (Evenity).
Read clinical reviewA clinical guide to transitioning pediatric patients (under age 12) treated with romosozumab into adult bone-health care programs, including monitoring protocols, dosing considerations, and evidence-based handoff strategies.
Read clinical review